Today: 18 January 2026
Subscribe
Browse Category

Biotech News 2 October 2025 - 11 October 2025

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

Stock Performance & Recent Trends AbbVie’s stock closed at $230.88 on Oct. 10, 2025 Marketbeat. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50 Investing. Notably, on Sept. 30 ABBV hit a 52-week high around $244.8, buoyed by regulatory filings and a sector-wide rally. From that late-September peak it has pulled back into…
11 October 2025
····
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseases Protagonist Inc. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers…
11 October 2025
····
Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

In-Depth Analysis BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a proprietary RNA platform combining circular and linear RNA engineering with sophisticated lipid nanoparticle (LNP) delivery Bms Fiercebiotech. Its lead program, OTX-201, is designed as an in vivo CAR‑T:…
10 October 2025
····
Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Company Profile – Background & Leadership Turn Therapeutics, Inc. is a Westlake Village, CA-based biotech company founded in 2015 Renaissancecapital. The company (formerly named Global Health Solutions, Inc.) officially rebranded to Turn Therapeutics in Sept 2025 ahead of its Nasdaq listing Stockanalysis. Turn’s mission is to “turn the tides” in medicine by developing technologies that heal, not just manage, challenging traditional treatments Benzinga. CEO Bradley…
9 October 2025
····
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Therapy (Target) Indication Status (2025) Current Ownership TECELRA(afamitresgene, targets MAGE-A4) Synovial sarcoma (unresectable/metastatic) FDA approved Aug 2024 Biospace; ~16 patients treated in launch year Nasdaq. Sold to US WorldMeds (2025) Adaptimmune Letetresgene (lete-cel, NY-ESO-1) MRCLS and synovial sarcoma (advanced solid tumors) Phase II completed (42% response rate) Stocktitan; FDA Breakthroughdesignation in 2025 Stocktitan; BLA filing planned for 2025. Sold to US WorldMeds (2025) Adaptimmune Uzatresegene…
8 October 2025
····
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Recent Stock Performance & Surge on Data Dyne Therapeutics’ stock has been on a tear following its latest clinical breakthroughs. Shares jumped 10–11% intraday on October 7, 2025, after the company reported positive one-year results from a key trial, lifting the stock to about $14.02 by mid-day Marketbeat Marketbeat. This rally builds on a strong upward trend in recent months…
7 October 2025
····
Galecto Stock Skyrockets 600% – Short Squeeze Mania or Biotech Breakthrough?

Galecto Stock Skyrockets 600% – Short Squeeze Mania or Biotech Breakthrough?

GLTO’s 632% Stock Spike: What Just Happened? Galecto’s stock made headlines on October 7, 2025 by soaring roughly six-fold in value within hours. In pre-market trading that morning, GLTO was up about 632% at one point Stocktwits Stocktwits. Shares that had closed around $3–4 the prior day suddenly traded in the high teens, hitting over two-year highs Stocktwits Stocktwits. Crucially, no new announcement or fundamental development…
7 October 2025
···
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Stock Performance & Recent Price Action Spruce Biosciences’ stock has been on a wild ride in early October 2025. Heading into this period, SPRB was a little-known micro-cap biotech trading in the high single digits (post-reverse-split). At the close on Oct 3, 2025, shares stood at $8.82 (market cap ~$4.8M) Stocktitan after a period of relatively low activity. That calm…
6 October 2025
····
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring?

2025 Year‑to‑Date Stock Performance Cidara’s stock has been among the best performers in biotech. According to YTDReturn.com, a US$10,000 investment on 31 Dec 2024 would have grown to ~US$37,943 by 3 Oct 2025 because the share price increased from US$26.88 to US$101.99, a 279.43 % YTD return Ytdreturn. Zacks similarly reported a 217.8 % YTD rally by late September Nasdaq, reflecting further gains in October. The…
4 October 2025
·····
Regencell (RGC) Stock Skyrockets 64,000% – Miracle Biotech or Bubble?

Regencell (RGC) Stock Skyrockets 64,000% – Miracle Biotech or Bubble?

RGC’s 2025 Rollercoaster: From Penny Stock to $33B Phenomenon Regencell Bioscience’s journey in 2025 has been nothing short of astonishing. The company went from an obscure penny stock (literally trading under 10 cents) to a meteoric high of $83.60 within months Stockanalysis. This 820-fold increase was “far stranger” than a typical biotech breakthrough – it happened without any major scientific…
4 October 2025
····
Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast’s stock has surged recently on the Ryoncil news. At the Oct 2 close it stood at $17.02 – up +4.6% on the day and roughly +8% from two weeks prior Stockinvest Marketbeat. This rally follows last week’s announcements: on Sept 26 the company announced its therapies are U.S.-origin and exempt from tariffs Nasdaq, and on Oct 2 it disclosed…
3 October 2025
·····
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Stock Performance and Trends Sarepta’s stock is recovering some ground after steep losses. As of Oct 2, 2025, SRPT closed at $19.57, up about 6.8%for the day Investing. This followed a general uptrend in recent weeks: SRPT is up roughly 16% over the last month Marketbeat (though still down >80% from early 2025 levels). Trading volume has been moderate (0.6 million on Oct 2 vs.…
2 October 2025
····
1 … 8 9 10 11 12

Stock Market Today

  • IREN shares jump 11% on Friday as MLK Day market break looms; Microsoft AI deal, crypto outlook in focus
    January 18, 2026, 1:38 PM EST. IREN Limited shares jumped 11.4% to $57.82 on Friday, with a 0.8% gain in after-hours trade. U.S. markets were closed Monday for MLK Day; trading resumes Tuesday. The move followed an upgrade by H.C. Wainwright & Co. from sell to buy on Jan. 13 and a Microsoft AI cloud deal valued around $9.7 billion that gives access to Nvidia GPUs via Dell for AI work. IREN runs renewable-powered data centers and mines crypto while offering AI cloud services; Reuters notes it uses about 1,896 Nvidia GPUs. Friday's action was volatile: intraday swing from $51.85 to $58.74 on about 54 million shares. Peers Riot Platforms and Marathon Digital rose on the same theme, including AMD data-center leases. Risks include large capex, higher power costs, crypto-price moves, and potential delivery delays. Earnings due Feb. 11-12 per MarketBeat.
Go toTop